麗珠醫藥(01513.HK)上半年純利升5.75%至10.62億元
格隆匯8月24日丨麗珠醫藥(01513.HK)公佈中期業績，截至2021年6月30日止6個月，公司營業收入為人民幣62.36億元，同比增長22.38%；歸屬於公司股東的淨利潤為人民幣10.62億元，同比增長5.75%；歸屬於公司股東的扣除非經常性損益的淨利潤為人民幣9.20億元，同比增長10.25%；基本每股收益為人民幣1.14元。
報吿期，集團主營業務實現收入人民幣61.94億元，同比增長2.15%。其中，化學制劑產品同比增長61.12%，原料藥和中間體產品同比增長19.17%。
報吿期，重點製劑產品的銷售收入及同比變動情況如下：促性激素領域中的重點產品注射用醋酸亮丙瑞林微球實現銷售收入人民幣8.18億元，同比增長52.49%；注射用尿促卵泡素實現銷售收入人民幣3.08億元，同比增長70.14%。消化道領域的重點產品艾普拉唑系列實現銷售收入人民幣15.31億元，同比增長130.64%；雷貝拉唑鈉腸溶膠囊實現銷售收入人民幣9840萬元，同比下降9.92%；得樂系列實現銷售收入人民幣1.29億元，同比增長27.48%；麗珠維三聯實現銷售收入人民幣1.57億元，同比增長65.67%。精神領域的重點產品馬來酸氟伏沙明片及鹽酸哌羅匹隆片分別實現銷售收入人民幣1.14億元和人民幣8056萬元，同比增長分別為40.67%和77.21%。抗感染領域的重點產品注射用伏立康唑實現銷售收入人民幣1.15億元，同比增長9.00%。中藥製劑領域產品參芪扶正注射液實現銷售收入人民幣299.03百萬元，同比增長11.27%；抗病毒顆粒實現銷售收入人民幣228.00百萬元，同比下降24.57%。
原料藥及中間體重點產品的收入及同比變動情況如下：苯丙氨酸實現銷售收入人民幣2.03億元，同比增長17.62%；阿卡波糖實現銷售收入人民幣6931萬元，同比下降38.89%；鹽酸萬古黴素實現銷售收入人民幣9751萬元，同比增長15.07%；達託黴素實現銷售收入人民幣1.18億元，同比增長90.40%；林可黴素實現銷售收入人民幣5764萬元，同比增長48.96%；米爾貝肟實現銷售收入人民幣4991萬元，同比增長6.53%；美伐他汀實現銷售收入人民幣7526萬元，同比增長142.34%。
集團主營業務收入增長主要是集團不斷深化營銷改革，全力推進產品渠道下沉，加快銷售專科領域建設，化學制劑板塊重點高毛利品種銷量穩定增長，總體增速顯着，同時通過資源整合、調整產品結構、加大國際認證等措施，原料藥板塊銷量穩中有升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
